FOXOD · Foxo Technologies Inc.
Substantial doubt about the company's ability to continue as a going concern.
“until additional equity or debt capital is secured and the Company begins generating sufficient revenue and operating cash flows, there is substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed May 15, 2026
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FOXOD
this stock
Foxo Technologies Inc.
|
$42,616 | -86.7% | +304.0% | — | 0.1% |
|
HCA
HCA Healthcare, Inc.
|
$92.77B | -12.4% | +7.1% | 14.4 | 2.6% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.63B | -10.8% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.19B | +29.6% | -2.3% | 13.4 | 3.5% |
|
DVA
Davita Inc.
|
$15.37B | +112.1% | +6.5% | 22.4 | 7.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- +181 sh
- Top holder
- SABBY MANAGEMENT, LLC
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FOXOD | +33.3% | -86.7% | -86.7% | -86.7% | -86.7% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +35.7% | -84.4% | -93.0% | -84.4% | -93.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.